Literature DB >> 3308173

Methotrexate in the treatment of arthritis and connective tissue diseases.

W S Wilke, J A Biro, A M Segal.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3308173     DOI: 10.3949/ccjm.54.4.327

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


× No keyword cloud information.
  5 in total

1.  Interleukin-1beta (IL-1beta) inhibition: a possible mechanism for the anti-inflammatory potency of liposomally conjugated methotrexate formulations in arthritis.

Authors:  A S Williams; S G Jones; R M Goodfellow; N Amos; B D Williams
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

2.  Methotrexate does not increase the risk of liver fibrosis in patients with rheumatoid arthritis: assessment by ultrasound elastography (ARFI-MetRA study).

Authors:  Martin Feuchtenberger; Lisa Kraus; Axel Nigg; Hendrik Schulze-Koops; Arne Schäfer
Journal:  Rheumatol Int       Date:  2021-02-20       Impact factor: 2.631

3.  Methotrexate treatment in murine experimental systemic lupus erythematosus (SLE); clinical benefits associated with cytokine manipulation.

Authors:  R Segal; M Dayan; H Zinger; E Mozes
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

4.  Methotrexate-Related Liver Cirrhosis in Psoriatic Arthritis: A Case Report and Review of the Literature.

Authors:  Maria-Loukia Koutsompina; Maria Pappa; Stratigoula Sakellariou; Chrysoula G Gialouri; George E Fragoulis; Theodoros Androutsakos
Journal:  Mediterr J Rheumatol       Date:  2021-09-07

Review 5.  Risk of liver disease in methotrexate treated patients.

Authors:  Richard Conway; John J Carey
Journal:  World J Hepatol       Date:  2017-09-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.